We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Rapid Molecular Diagnostic Platform Sends Precise COVID-19 RNA Results to Smartphone in Minutes

By HospiMedica International staff writers
Posted on 05 Mar 2021
An all new technology can detect COVID-19 RNA in saliva through newly developed electronic nanosensors, which significantly reduces error rates associated with chemical-based home tests.

IdentifySensors Biologics (Cleveland, OH, USA), a nanosensor technology firm which has developed the rapid diagnostic platform for detecting pathogens, including SARS-CoV-2, has now joined the SMART Film Consortium, led by the Birck Nanotechnology Center at Purdue University (West Lafayette, IN, USA) that seeks to develop the first foundry dedicated to low-cost non-silicon printed sensors. More...


Unlike other molecular tests for COVID-19, the rapid molecular diagnostic platform automatically transmits test results to consumer smartphones and to the proper health agencies in minutes. The platform technology can be easily modified to also detect influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox and methicillin-resistant staphylococcus Aureus (MRSA) and foodborne pathogens.

"By joining the SMART Film Consortium, IdentifySensors Biologics has positioned itself in a significantly strategic vantage point where it is able to tap into a wide array of printing and scalable manufacturing resources in the Birck Nanotechnology Center to greatly accelerate the development of their COVID-19 sensor," said Thomas Sors, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease.

Related Links:
IdentifySensors Biologics
Purdue Research Foundation



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.